Caribbean Eye Meeting 2022

James C. Loden, MD

Founder and President
Loden iVision Centers
Nashville, TN

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

The following faculty/staff members have the following financial relationships with ineligible companies.

James C. Loden, MD, has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Johnson & Johnson and Lensar. Grant/Research Support: Bausch & Lomb, Lenstec, and Johnson & Johnson Vision.

Shamik Bafna, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bearer Visitec, Carl Zeiss Meditec, Sight Sciences, and Ivantis. Speaker’s Bureau: Rx Sight.

Patty Barkey, COE has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Biotissue, Sun Pharmaceuticals, Johnson & Johnson, and Science Based Health.

William Bond, MD has no financial relationships with ineligible companies.

Frank Bowden, MD has a financial agreement or affiliation with the following ineligible companies in the form of Speaker: Sun Pharmaceuticals, Bausch + Lomb, and Kala.

Frank Bucci, MD has a financial agreement or affiliation with the following ineligible companies in the form of Grant/Research Support: Johnson & Johnson Vision.

Jack Chapman Jr, MD has a financial agreement or affiliation with the following ineligible companies in the form of Advisory Board: RVL Pharmaceuticals. Consultant: Alcon, RVL Pharmaceuticals, Santen/EyeVance Pharmaceuticals, and Sun Pharmaceuticals. Grant/Research Support: Alcon. Speakers Bureau: Alcon, RVL Pharmaceuticals, and Sun Pharmaceuticals.

Kendall Donaldson, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Johnson and Johnson, Avellino, Science Based Health, LensAR, Tissue Tech, Acufocus, Bausch + Lomb, Lumenis, Eyevance, Novartis, Quidel, and Carl Zeiss Meditec.

Lisa Feulner, MD, PhD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Allergan/Abbvie, Bausch + Lomb, Kala Pharmaceuticals, Novaris, Oyster Point, RVL/Osmotica, Sun Pharma, Carl Zeiss Meditec, Aldeyra, Bruder, and Orasis. Speakers Bureau: Allergan/Abbvie, Bausch + Lomb, Kala Pharmaceuticals, Novartis, and Sun Pharma.

Tom Frinzi has a financial agreement or affiliation with the following ineligible companies in the form of Shareholder and Advisory Board: Staar Surgical, iOR Partners, CorneaGen, ViaLase, and Aurion Biotech.

Eric Fry, MD has no financial relationships with ineligible companies.

Timothy Giles, OD, MBA has no financial relationships with ineligible companies.

Steve Gottfredson, BS has a financial agreement or affiliation with the following ineligible companies in the form of Employee: Brevium.

Arun Gulani, MD has a financial agreement or affiliation with the following ineligible companies in the form of Speakers Bureau: Oculus and Tracey Technologies.

Collin Hart, MBA has no financial relationships with ineligible companies.

Arjun Hura, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon Vision and Tarsus Pharmaceuticals. Grant/Research Support: Alcon Vision.

Mitchell Jackson, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant and Speakers Bureau: Bausch + Lomb, Ocular Innovations, Johnson & Johnson, and Alcon.

Carrie Jacobs, COE, CPSS, OCS has no financial relationships with ineligible companies.

Anish Kapur, MD has a financial agreement or affiliation with the following ineligible companies in the form of Employee and Shareholder: FocalPoint Holdings, LLC and Promptly LLC.

James Katz, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant and Advisor: Alcon, Allergan, Avellino Labs, Bausch + Lomb, Carl Zeiss Meditec, Cassini Technologies B.V., Centricity Vision, Eyevance Pharmaceuticals, Johnson & Johnson Vision, Kala Pharmaceuticals, LEGRANDE Health, Lenticular Research Group, Novartis, Ocular Science, Ocuphire Pharma, Refocus Group, Tarsus Pharmaceuticals, and Visus Therapeutics. Grant/Research Support: Allergan, Cassini Technologies B.V., and Refocus Group. Speaker: Alcon and Novartis. Shareholder: Centricity Vision, Inc, LEGRANDE Health, Lenticular Research Group, Ocular Science, Orasis Pharmaceuticals, and Tarsus Pharmaceuticals.

Mark Kontos, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant and Speakers Bureau: Johnson & Johnson, Alcon, Allergan, Carl Zeiss Meditec, Glaukos, and Orasis.

Ivan Mac, MD, MBA has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: TearLab, Alcon, Allergan, I-Med Pharma, Tarsus Pharmaceuticals, Staar Surgical, Sun Pharmaceuticals, and Ellex Inc. Speakers Bureau: Alcon. Shareholder: RxSight, Tarsus Pharmaceuticals and Visionary Venture Group.

Cynthia Matossian, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alcon, Allergan, Aramis Biosciences, Bausch + Lomb, Bruder Healthcare, Checked-Up, Conclusn, Dompe, EyePoint Pharmaceuticals, EyeVance, Glint Pharmaceuticals, Guardion Health Services, Imprimis Pharmaceuticals, Johnson & Johnson, Kala Pharmaceuticals, LacriSciences Vision, legrande Health, Lenstec, lumenis, Marco, MDBackline, MiCare, MYZE, Novartis, NuLids, LLC, Ocular Science, Olympic, Omeros, Osmotica Pharmaceuticals, Physician Recommended Nutriceuticals, Quidel, Reger-Eyes, StepWise Medical, Sun Pharmaceuticals, TearLab, TearScience, TissueTech, Visionology, Visus Therapeutics, and Carl Zeiss Meditec. Grant/Research Support: Dompe, Imprimis Pharmaceuticals, Johnson & Johnson, and Novartis. Speakers Bureau: Alcon, Allergan, EyePoint Pharmaceuticals, EyeVance, Guardion Health Services, Imprimis Pharmaceuticals, Johnson & Johnson, Kala Pharmaceuticals, LacriSciences Vision, Lumenis, Novartis, NuLids, LLC, Olympic, Omeros, Physician Recommended Nutriceuticals, Sun Pharmaceuticals, TearLab, TearScience, TissueTech, and Carl Zeiss Meditec. Shareholder: Checked-Up, Physician Recommended Nutriceuticals, and Strathspey Crown.

Cathleen McCabe, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Alcon, Bausch + Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis Pharma, Ocular Innovations, Ocular Therapeutix, Omeros, Science Based Health, Sight Sciences, Sun Ophthalmics, Tarsus, and Carl Zeiss Meditec. Grant/Research Support: AbbVie/Allergan, Alcon, EyePoint Pharmaceuticals, Glaukos Corp, Ivantis, Johnson & Johnson, Ocular Therapeutix, and Ora Inc. Speakers Bureau: Alcon, Bausch + Lomb, EyePoint Pharmaceuticals, Glaukos Corp, Ivantis, Novartis Pharma, Ocular Therapeutix, Omeros, Sun Opthalmics, and Carl Zeiss Meditec.

Beeran Meghpara, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Allergan, CorneaGen, Eyevance, Kala, Oculus, Ocular Therapeutix, Sight Sciences, Sun Pharma, Tarsus, and WL Gore & Associates. Speaker’s Bureau: Allergan, Dompe, Eyevance, and Tarsus.

J. Morgan Micheletti, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon and Allergan. Grant/Research Support: Alcon, Johnson & Johnson Vision, and Allergan. Speaker: Diamatrix and Glaukos.

T. Hunter Newsom, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Rx Sight Inc. Grant/Research Support: Alcon.

Sheri Rowen, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Oyster Point, Kala, Johnson & Johnson, Novartis, Azura, Ocuterra, Orasis, and Carl Zeiss Meditec. Grant/Research Support: Alcon and Novartis. Speakers Bureau: Alcon, Bausch + Lomb, and Kala. Shareholder: Ocuterra and Orasis.

Inder Paul Singh, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Aerie, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Elios, Glaukos, Ivantis, MMD, New World Medical, Ocular Therapeutix, Santen, and Sight Sciences. Speaker: Aerie, Allergan, Bausch + Lomb, Ivantis, Ocular Therapeutix, and Sight Sciences. Shareholder: CoFI.

Mitchell Shultz, MD has a financial agreement or affiliation with the following ineligible companies Consultant: Ivantis/Alcon, Glaukos, New World Medical, Bausch + Lomb, Tarsus, Allergan, HDMD and RxSight. Grant/Research Support: Glaukos, New World Medical, Bausch + Lomb, and Tarsus. Speakers Bureau: Ivantis/Alcon, Glaukos, Sight Science, New World Medical, Bausch + Lomb, Sun Pharmaceuticals, and RxSight. Shareholder: Alchemy Vision Project.

Allison Shuren, JD has no financial relationships with ineligible companies.

John David Stephens, MD has no financial relationships with ineligible companies.

P Dee Stephenson, MD has a financial agreement or affiliation with the following ineligible companies in the form Consultant: LENSAR, Carl Zeiss Meditec, and Atia. Grant/Research Support: BEL. Speakers Bureau: Alcon, BEL, Brusden, Cassini, Eyevance, Guardian Health, Kala, LENSAR, Ocular Therapuetix, Omeros, Sun, Carl Zeiss Meditec. Shareholder: Eyevance and Guardian Health.

Wes Strickling has no financial relationships with ineligible companies.

Denise Visco, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: LENSAR, Inc, Carl Zeiss Meditec, Oyster Point Pharma, Bausch + Lomb, Omeros, Sun Opththalmic, Cassini, Inc. Grant/Research Support: LENSAR, Inc and Oyster Point Pharma. Advisory Board: Carl Zeiss Meditec.

Caroline Watson, MD has a financial agreement or affiliation with the following ineligible companies in the form Consultant: Alcon, Tarsus, Visus Therapeutics, and MicroSurgical Technologies.

Robert Weinstock, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Lensar, Bausch + Lomb, Alcon, Johnson & Johnson Vision, EyePoint Pharmaceuticals, Beyeonics, Omeros, and Visus. Speakers Bureau: Johnson & Johnson Vision. Shareholder: RxSight, RPS, EyeSafe, Pogotec, UBeam, Tissuetech and Visus.

Jeffrey Whitman, MD has a financial agreement or affiliation with the following ineligible companies in the form Consultant: Bausch + Lomb and EyePoint Pharmaceuticals. Grant/Research Support: Alcon. Speakers Bureau: Alcon and Johnson & Johnson.

William Wiley, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, RXSight, Johnson & Johnson, Allergan, Carl Zeiss Meditec, Bausch + Lomb, Imprimis, and Rayner. Grant/Research Support: RxSight, Carl Zeiss Meditec, and Imprimis.

Blake Williamson, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, New World Medical, Quidel Corporation, and Sight Sciences. Speaker: Glaukos.

Gary Wortz, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Omega Ophthalmics, LLC and Bausch + Lomb. Speakers Bureau: Bausch + Lomb and Johnson & Johnson. Shareholder: Arcuate Innovations, LLC and Omega Ophthalmics, LLC.

Jennifer Hodge, Co-Director of Compliance and Education, Evolve; Donna McCune, Executive Director, the Society for Excellence in Eyecare (SEE); Gilbert Wheeler, Executive Director, the American College of Eye Surgeons (ACES), the American Board of Eye Surgery (ABES) have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.